Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

12.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
12.4K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

13.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
13.5K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
T Cell Types and Functions01:24

T Cell Types and Functions

1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

77.8K
Overview
77.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automating neoantigen selection for personalized cancer vaccine design.

medRxiv : the preprint server for health sciences·2026
Same author

pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design.

ArXiv·2026
Same author

Immune Checkpoint Therapy Drives Maturation of a Cellular Neighborhood Nucleated by T Cell-APC Triads Enabling Spatially Compartmentalized Tumor Immunity.

bioRxiv : the preprint server for biology·2026
Same author

mRNA vaccines engage unconventional pathways in CD8<sup>+</sup> T cell priming.

Nature·2026
Same author

CD8<sup>+</sup> T cells are primed by cDC1 and exacerbate tau-mediated neurodegeneration.

bioRxiv : the preprint server for biology·2026
Same author

Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.

Cancer immunology research·2026

Related Experiment Video

Updated: Nov 2, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

966

Bcl6-Independent In Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection.

Prachi Bagadia1, Kevin W O'Connor2, Renee Wu2

  • 1Department of Oncology, Amgen Inc., South San Francisco, CA.

Journal of Immunology (Baltimore, Md. : 1950)
|June 17, 2021
PubMed
Summary

The transcriptional repressor Bcl6 is needed in vitro for dendritic cell development but not in vivo. Bcl6 deficiency selectively reduces CD8α expression in cDC1 cells without impacting their overall development or function.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.9K

Related Experiment Videos

Last Updated: Nov 2, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

966
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.9K

Area of Science:

  • Immunology
  • Cell Biology
  • Developmental Biology

Background:

  • Classical dendritic cells (cDCs), specifically cDC1, are crucial for cross-presentation.
  • The transcriptional repressor Bcl6 has been implicated in cDC1 development, but in vivo mechanisms remain unclear.

Purpose of the Study:

  • To investigate the in vivo role of Bcl6 in mouse classical dendritic cell (cDC) development, particularly cDC1.
  • To elucidate the mechanisms by which Bcl6 influences cDC1 function and marker expression.

Main Methods:

  • Conditional deletion of the Bcl6 gene in mouse cDCs.
  • Analysis of cDC development, marker expression (CD8α, XCR1, CD24), and in vivo functions like tumor rejection and T cell priming in Bcl6-deficient mice.

Main Results:

  • Bcl6 deficiency confirmed in vitro requirement for cDC1 development and general role in competitive cDC development.
  • In vivo deletion of Bcl6 did not prevent cDC1 development, but selectively reduced CD8α expression.
  • Normal cDC1 development and function, including tumor rejection and CD8 T cell priming, were observed in Bcl6-deficient mice.

Conclusions:

  • Bcl6 is required in vitro but not in vivo for the development of cDC1.
  • Bcl6 regulates a subset of cDC1-specific markers, including CD8α expression, but is not essential for overall cDC1 development or anti-tumor immunity.